(Q53916207)

22 May 2018

title

Long-term remission of APL with a second allogeneic BMT after CNS relapse following HLA-identical allogeneic BMT. (English)

1 reference

22 May 2018

author

Klaus-Michael Debatin

2

1 reference

22 May 2018

author name string

Classen CF

1

1 reference

22 May 2018

Friedrich W

3

1 reference

22 May 2018

Schulz AS

4

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 October 2003

1 reference

22 May 2018

Bone Marrow Transplantation

published in

1 reference

22 May 2018

volume

32

1 reference

22 May 2018

issue

8

1 reference

22 May 2018

page(s)

843-846

1 reference

22 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704225

exact match

0 references

cites work

Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

The role of bone marrow transplantation in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

7 January 2021

Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

7 January 2021

Microgranular variant of acute promyelocytic leukemia in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

7 January 2021

Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

7 January 2021

Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

7 January 2021

In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704225

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704225

1 reference

22 May 2018

1 reference

22 May 2018